BusinessKura Oncology to Participate in Three Upcoming Investor ConferencesBy Nasdaq OMXFeb 9, 2017, 9:07 PM UTC
BusinessKura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Chronic Myelomonocytic LeukemiaBy Nasdaq OMXJan 17, 2017, 12:30 PM UTC
BusinessKura Oncology Receives FDA Clearance to Proceed with Clinical Trial for ERK Inhibitor KO-947 and Nominates KO-539 as Development Candidate for Menin-MLL Inhibitor ProgramBy Nasdaq OMXJan 4, 2017, 12:30 PM UTC
BusinessKura Oncology Appoints Steven Stein, M.D. to Board of DirectorsBy Nasdaq OMXJan 3, 2017, 9:06 PM UTC
BusinessKura Oncology Appoints Steven Stein, M.D. to Board of DirectorsBy Nasdaq OMXJan 3, 2017, 9:06 PM UTC
BusinessKura Oncology Presents Preclinical Data on KO-947 and Menin-MLL Inhibitor Program at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsBy Nasdaq OMXDec 1, 2016, 12:30 PM UTC
BusinessKura Oncology to Participate in the 5th Annual Gateway ConferenceBy Nasdaq OMXSep 2, 2016, 11:30 AM UTC
